The size of the Nuclear Imaging Market in the Asia Pacific was worth USD 3.71 billion in 2019 and estimated to be growing at a CAGR of 9.64%, to reach USD 5.88 billion by 2024.
Medical imaging is the method of generating a photographic image of the inside of the body for medical intervention. These devices aid in creating a databank of normal anatomy and physiology of internal organs so that any irregularity can be observed immediately.
Nuclear imaging is most commonly utilized for cardiovascular and oncology applications. It refers to the method of generating visuals of the organs of the body by processing a minor quantity of radioactive tracers. The images are obtained using a gamma camera and can be documented on film or on a computer.
The growth of the Asia-Pacific Nuclear Imaging market is mainly due to factors such as an increase in the number of cancer and cardiovascular disease cases, predilection towards minimally invasive procedures, the ready availability of radiopharmaceuticals, and improving healthcare infrastructure in developing markets.
However, factors such as costly procedures & equipment, inadequate number of trained medical staff, and shortage of supplies are hampering the growth of the market in this region.
This research report has been segmented & sub-segmented into the following categories:
Among Asia-Pacific countries, India, Japan, and Australia will be the substantial markets due to growing healthcare budgets and the rising popularity of several radiopharmaceuticals in numerous clinical indications.
The major companies dominating the APAC Nuclear Imaging market in this region are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Technologies
5.1.1 Introduction
5.1.2 PET Radioisotopes
5.1.2.1 Rubidium-82
5.1.2.2 Fluorine-18
5.1.2.3 Others
5.1.3 SPECT Radioisotopes
5.1.3.1 Thallium-201
5.1.3.2 Technetium-99m
5.1.3.3 Xenon-133
5.1.3.4 Iodine-123
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Diagnostic Technologies
5.1.5 Market Attractiveness Analysis, By Diagnostic Technologies
5.1.6 Market Share Analysis, By Diagnostic Technologies
5.2 Application
5.2.1 Introduction
5.2.2 PET
5.2.2.1 Cardiology
5.2.2.2 Oncology
5.2.2.3 Neurology
5.2.2.4 Others
5.2.3 SPECT
5.2.3.1 Lymphoma
5.2.3.2 Neurology
5.2.3.3 Cardiology
5.2.3.4 Thyroid
5.2.3.5 Others
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Technologies
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Technologies
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Technologies
6.1.5.3 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Mallinckrodt plc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Siemens Medical Solutions
8.3 Hitachi Medical Corporation
8.4 Medtronic Inc.
8.5 General Electric Co. (healthcare division)
8.6 IBA Group
8.7 Positron Corporation
8.8 Philips Medical Systems
8.9 Naviscan
8.10 Toshiba Medical Systems Corporation
8.11 Carestream Health
8.12 Lantheus Medical Imaging Inc.
8.13 Cardinal Health Inc.
8.14 Bayer AG
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
